NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free NEPH Stock Alerts $2.16 -0.03 (-1.37%) (As of 03:00 PM ET) Add Compare Share Share Today's Range$2.16▼$2.3150-Day Range$1.99▼$3.7252-Week Range$1.13▼$4.04Volume3,915 shsAverage Volume18,958 shsMarket Capitalization$22.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Nephros alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Nephros Stock (NASDAQ:NEPH)Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More NEPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEPH Stock News HeadlinesApril 23, 2024 | finance.yahoo.comNephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 20, 2024 | finance.yahoo.comNephros, Inc. (NEPH) Interactive Stock Chart - Yahoo FinanceApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 19, 2024 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) Profit OutlookApril 16, 2024 | americanbankingnews.comNephros (NASDAQ:NEPH) Shares Down 0.5% March 11, 2024 | finanznachrichten.deNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 10, 2024 | finance.yahoo.comNephros Full Year 2023 Earnings: Misses ExpectationsMarch 9, 2024 | markets.businessinsider.comNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 9, 2024 | markets.businessinsider.comNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingMarch 8, 2024 | realmoney.thestreet.comNephros just upgraded at Benchmark, here's whyMarch 8, 2024 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comNEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | globenewswire.comNephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 6, 2024 | benzinga.comEarnings Outlook For NephrosMarch 6, 2024 | markets.businessinsider.comNephros earnings: here's what to expectFebruary 29, 2024 | globenewswire.comNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsJanuary 28, 2024 | finance.yahoo.comWhat Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?January 24, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerJanuary 24, 2024 | finance.yahoo.comRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerDecember 18, 2023 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price BounceDecember 14, 2023 | morningstar.comNephros Inc NEPHDecember 13, 2023 | finance.yahoo.comAre Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?December 12, 2023 | msn.comNephros CEO buys 18k shares of the company - filingDecember 12, 2023 | msn.comTraeger heats up after attracting bull rating from B. RileyNovember 27, 2023 | msn.comNephros (NEPH) Price Target Increased by 50.00% to 4.59November 22, 2023 | markets.businessinsider.comBenchmark Co. Keeps Their Hold Rating on Nephros (NEPH)See More Headlines Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/26/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-11.06% Pretax Margin-11.06% Return on Equity-18.25% Return on Assets-14.29% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio2.81 Sales & Book Value Annual Sales$14.24 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book2.74Miscellaneous Outstanding Shares10,540,000Free Float10,112,000Market Cap$23.08 million OptionableNot Optionable Beta1.30 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert Banks (Age 49)President, CEO & Director Comp: $474.04kMs. Judy F. Krandel C.F.A. (Age 59)Chief Financial Officer Comp: $147.01kMr. Alfred VargasDirector of OperationsBrianne McGuireDirector of Brand, Marketing & Business DevelopmentVashone R. ThomasVice President of Quality, Regulatory, & Human ResourcesMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Executive Officer of Specialty Renal Products, Inc Comp: $300.18kMr. Greg LucasPresident of Aether Water SystemsMs. Judy MazziniControllerMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDInspira Technologies Oxy B.H.N.NASDAQ:IINNGlucoTrackNASDAQ:GCTKAkiliNASDAQ:AKLISTRATA Skin SciencesNASDAQ:SSKNView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 15,383 shares on 4/26/2024Ownership: 0.146%Robert R Jr. BanksBought 18,000 shares on 12/7/2023Total: $39,600.00 ($2.20/share)Robert R Jr. BanksBought 99 shares on 8/14/2023Total: $148.50 ($1.50/share)View All Insider TransactionsView All Institutional Transactions NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed in 2024? Nephros' stock was trading at $3.46 on January 1st, 2024. Since then, NEPH shares have decreased by 37.6% and is now trading at $2.16. View the best growth stocks for 2024 here. Are investors shorting Nephros? Nephros saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,600 shares, a decline of 38.5% from the March 31st total of 2,600 shares. Based on an average daily trading volume, of 18,800 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are short sold. View Nephros' Short Interest. When is Nephros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NEPH earnings forecast. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.06) EPS for the quarter. The business had revenue of $3.25 million for the quarter. Nephros had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 18.25%. Who are Nephros' major shareholders? Nephros' stock is owned by many different institutional and retail investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.15%). Insiders that own company stock include Andrew Astor, Robert R Jr Banks, Tom Gwydir and Wesley S Lobo. View institutional ownership trends. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEPH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.